NASDAQ:INBX Inhibrx (INBX) Stock Price, News & Analysis $13.73 +0.30 (+2.23%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$13.27▼$13.7350-Day Range$12.88▼$34.4652-Week Range$12.61▼$18.95Volume25,072 shsAverage Volume155,007 shsMarket Capitalization$198.81 millionP/E RatioN/ADividend YieldN/APrice Target$27.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Inhibrx alerts: Email Address Inhibrx MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside96.6% Upside$27.00 Price TargetShort InterestBearish7.24% of Float Sold ShortDividend StrengthN/ASustainability-1.21Upright™ Environmental ScoreNews Sentiment1.10Based on 6 Articles This WeekInsider TradingSelling Shares$10.29 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.24 out of 5 starsMedical Sector161st out of 936 stocks 3.0 Analyst's Opinion Consensus RatingInhibrx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageInhibrx has only been the subject of 1 research reports in the past 90 days.Read more about Inhibrx's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.24% of the float of Inhibrx has been sold short.Short Interest Ratio / Days to CoverInhibrx has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldInhibrx does not currently pay a dividend.Dividend GrowthInhibrx does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInhibrx has received a 71.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for deficiency diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Inhibrx is -1.21. Previous Next 2.8 News and Social Media Coverage News SentimentInhibrx has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Inhibrx this week, compared to 1 article on an average week. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inhibrx insiders have sold 932.36% more of their company's stock than they have bought. Specifically, they have bought $996,749.00 in company stock and sold $10,290,000.00 in company stock.Percentage Held by Insiders22.20% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inhibrx's insider trading history. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Inhibrx Stock (NASDAQ:INBX)Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Read More INBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INBX Stock News HeadlinesJuly 24 at 4:47 PM | msn.comJMP Securities Initiates Coverage of Inhibrx Biosciences (INBX) with Market Perform RecommendationJuly 24 at 10:50 AM | americanbankingnews.comInhibrx (NASDAQ:INBX) Coverage Initiated by Analysts at JMP SecuritiesJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.June 7, 2024 | seekingalpha.comInhibrx: Continued Advancement Even After INBRX-101 Sale To SanofiJune 5, 2024 | benzinga.comTop 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)May 25, 2024 | finanznachrichten.deInhibrx, Inc.: Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiMay 24, 2024 | prnewswire.comInhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiMay 10, 2024 | finance.yahoo.comInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 10, 2024 | prnewswire.comInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffMay 9, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXMay 8, 2024 | prnewswire.comInhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated MergerApril 16, 2024 | msn.comAs more rare disease therapies launch, their prices are risingMarch 16, 2024 | finance.yahoo.comINBX Apr 2024 50.000 putMarch 16, 2024 | finance.yahoo.comINBX Apr 2024 55.000 callFebruary 29, 2024 | realmoney.thestreet.comInhibrx just downgraded at Jefferies, here's whyFebruary 28, 2024 | finanznachrichten.deInhibrx, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | prnewswire.comInhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsSee More Headlines Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry N/A Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INBX CUSIPN/A CIK1739614 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees166Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$27.00 Low Stock Price Target$27.00 Potential Upside/Downside+96.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares14,480,000Free Float11,262,000Market Cap$198.81 million OptionableOptionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Mark Paul Lappe (Age 57)Founder, Chairman, President & CEO Comp: $1.1MDr. Brendan P. Eckelman Ph.D. (Age 45)Founder & Chief Scientific Officer Comp: $769.25kMs. Kelly Devine Deck B.S. (Age 44)CPA, M.S., Executive VP & CFO Comp: $636.87kMr. Quinn L. DeverauxFounderDr. Ashraf Amanullah (Age 56)Executive VP & Chief Technical Operations Officer Ms. Leah Pollema J.D.VP, Corporate Secretary & General CounselDr. Charbel Helaihel Pharm.D.Vice President of Marketing & Commercial PlanningMr. Jeffrey J. JensenExecutive VP & Chief Clinical Operations OfficerMr. David Matly M.B.A.Executive VP and Chief Commercial & Business Development OfficerDr. Carlos Bais Ph.D.Executive Vice President of Translational SciencesMore ExecutivesKey CompetitorsClover Health InvestmentsNASDAQ:CLOVCureVacNASDAQ:CVACDianthus TherapeuticsNASDAQ:DNTHCytek BiosciencesNASDAQ:CTKBNuvation BioNYSE:NUVBView All CompetitorsInsiders & InstitutionsEquitec Proprietary Markets LLCSold 16,000 shares on 7/12/2024Ownership: 0.000%Jon Faiz KayyemBought 57,549 shares on 6/5/2024Total: $996,748.68 ($17.32/share)Brendan P EckelmanSold 300,000 sharesTotal: $10.29 M ($34.30/share)RA Capital Management L.P.Sold 2,094,370 shares on 5/17/2024Ownership: 5.019%California State Teachers Retirement SystemSold 557 shares on 5/16/2024Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions INBX Stock Analysis - Frequently Asked Questions How have INBX shares performed this year? Inhibrx's stock was trading at $38.00 on January 1st, 2024. Since then, INBX stock has decreased by 63.9% and is now trading at $13.73. View the best growth stocks for 2024 here. How were Inhibrx's earnings last quarter? Inhibrx, Inc. (NASDAQ:INBX) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.06. The firm earned $2.53 million during the quarter, compared to analyst estimates of $1 million. When did Inhibrx IPO? Inhibrx (INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are Inhibrx's major shareholders? Inhibrx's top institutional investors include Equitec Proprietary Markets LLC. Insiders that own company stock include Mark Lappe, Brendan P Eckelman, Jon Faiz Kayyem and Global Investors Lp Viking. View institutional ownership trends. How do I buy shares of Inhibrx? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Inhibrx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ) and Fastly (FSLY). This page (NASDAQ:INBX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
